Trial Profile
Phase IV, multicenter, prospective, randomized, open-label, controlled study on Landiolol in patients with septic shock resident in an Intensive Care Unit
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs Landiolol (Primary)
- Indications Tachycardia
- Focus Therapeutic Use
- Acronyms LANDI-SEP
- Sponsors AOP Orphan Pharmaceuticals AG
- 07 Jul 2022 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 30 Apr 2022 Status changed from recruiting to completed.
- 20 Apr 2022 This trial has been completed in Poland (End Date: 16 Feb 2022), according to European Clinical Trials Database record.